Search results

Skip to results

Type

Status

Last updated

Showing 1 to 15 of 60 results for ipilimumab

  1. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.

    Technology appraisal guidance
    Published
    27 July 2016
    View recommendations

    Sections for TA400

  2. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.

    Technology appraisal guidance
    Published
    23 July 2014
    View recommendations

    Sections for TA319

  3. Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma (TA268)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced melanoma in adults.

    Technology appraisal guidance
    Published
    12 December 2012
    View recommendations

    Sections for TA268

  4. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.

    Technology appraisal guidance
    Last updated
    12 September 2017
    View recommendations

    Sections for TA366

  5. Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA780)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults.

    Technology appraisal guidance
    Published
    24 March 2022
    View recommendations

    Sections for TA780

  6. Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma (TA818)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated unresectable malignant pleural mesothelioma in adults.

    Technology appraisal guidance
    Published
    17 August 2022
    View recommendations

    Sections for TA818

  7. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.

    Technology appraisal guidance
    Last updated
    12 September 2017
    View recommendations

    Sections for TA357

  8. Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA1065)

    Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.

    Technology appraisal guidance
    Published
    28 May 2025

    Sections for TA1065

  9. Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency (TA716)

    Evidence-based recommendations on nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency in adults.

    Technology appraisal guidance
    Published
    28 July 2021
    View recommendations

    Sections for TA716

  10. Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer (TA724)

    Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) and chemotherapy for untreated metastatic non-small-cell lung cancer.

    Technology appraisal guidance
    Published
    8 September 2021
    View recommendations

    Sections for TA724

  11. Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]

    In development [GID-TA11587] Expected publication date: 25 June 2025

    Technology appraisal guidance
    In development

  12. Melanoma: assessment and management (NG14)

    This guideline covers the assessment and management of melanoma (a type of skin cancer) in children, young people and adults. It aims to reduce variation in practice and improve survival.

    NICE guideline
    Last updated
    27 July 2022
    View recommendations

    Sections for NG14

  13. Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)

    Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults when systemically administered immunotherapies are not suitable.

    Technology appraisal guidance
    Published
    28 September 2016
    View recommendations

    Sections for TA410

  14. Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over (TA950)

    Evidence-based recommendations on nivolumab–relatlimab (Opdualag) for untreated advanced (unresectable or metastatic) melanoma in people 12 years and over.

    Technology appraisal guidance
    Published
    7 February 2024
    View recommendations

    Sections for TA950

  15. Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

    Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

    Technology appraisal guidance
    Published
    18 February 2016
    View recommendations

    Sections for TA384